Skip to main content
. Author manuscript; available in PMC: 2017 Aug 31.
Published in final edited form as: Adv Drug Deliv Rev. 2017 Jun 10;113:177–200. doi: 10.1016/j.addr.2017.06.002

Figure 2.

Figure 2

Concept of a mini nano drug. A, comparison of an antibody-targeted covalent drug delivery system with a peptide-targeted mini nano drug. B, cartoon displaying advantages of the mini nano drug over the parent nano drug in gaining access through size limiting passages and crowded extracellular matrix to reach a receptor for binding. C, example of modules built in a mini nano drug carrying AONs for blocking mRNA for HER2 synthesis. Platform (curved line): PMLA, molecular weight 50 kDa. Loading: 6 molecules AON; 16 molecules HER2 affine peptide; 160 molecules trileucine for mini nano drug release from endosome into cytoplasm. D, growth inhibition of HER2-positive human breast tumor in nude mice by the mini nano drug treatment. E, benefits expected from the mini nano drug vs. antibody containing nano drug. Modified from [23].